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Abstract
Background: The 2010 Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) guidelines are
the only Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines for cow’s
milk allergy (CMA). They indicate oral food challenge (OFC) as the reference test for diagnosis, and suggest the
choice of specific alternative formula in different clinical conditions. Their recommendations are flexible, both in
diagnosis and in treatment.
Objectives & methods: Using the Scopus citation records, we evaluated the influence of the DRACMA guidelines
on milk allergy literature. We also reviewed their impact on successive food allergy and CMA guidelines at national
and international level. We describe some economic consequences of their application.
Results: DRACMA are the most cited CMA guidelines, and the second cited guidelines on food allergy. Many
subsequent guidelines took stock of DRACMA’s metanalyses adapting recommendations to the local context.
Some of these chose not to consider OFC as an absolute requirement for the diagnosis of CMA. Studies on their
implementation show that in this case, the treatment costs may increase and there is a risk of overdiagnosis.
Interestingly, we observed a reduction in the cost of alternative formulas following the publication of the
DRACMA guidelines.
Conclusions: DRACMA reconciled international differences in the diagnosis and management of CMA. They
promoted a cultural debate, improved clinician’s knowledge of CMA, improved the quality of diagnosis and
care, reduced inappropriate practices, fostered the efficient use of resources, empowered patients, and influenced
some public policies. The accruing evidence on diagnosis and treatment of CMA necessitates their update in the
near future.
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Background
The mission of the World Allergy Organization (WAO) is
to advance excellence in clinical care, research, education
and training. Clinical practice guidelines are part of this
mission. In the last 10 years, WAO produced guidelines on
anaphylaxis, allergy prevention, urticaria, allergy training,
hereditary angioedema, and molecular diagnosis [1]. All of
these documents aim at deepening the clinician’s know-
ledge, improving the quality of diagnosis and care and re-
ducing inappropriate variation in practice. Application of
these guidelines may promote the efficient use of re-
sources, inform and empower patients and support public
policies [2]. However, their introduction into routine daily
practice requires a series of educational, social and political
steps. If not correctly implemented, the guidelines may fail
their objectives and patients may remain exposed to harm-
ful or unnecessary care [3]. Barriers to guideline imple-
mentation may be encountered at different levels [4]:
– Individual, as professionals may have difficulty
understanding the guidelines’ language; they may also
introduce personal bias in thinking, balancing benefits
and risks, and reaching different conclusions;
– Motivational, as different factors/barriers may
generate different motivational stages in individual
professionals;
– Relating to organizational context, for instance lack
of arrangements for continuous learning, and lack of
implementation tools;
– Social, for the interference of existing values and
cultures, and for the influence of the opinion of key
people;
– Economic, for insufficient or no reimbursement
arrangements, rewards, health care systems or
incentives.
To overcome these limitations, a series of educational
tools needs to be put into play. In this article, we will
evaluate the impact on real life of DRACMA, the GRADE
guidelines on diagnosis and treatment of CMA [5], and
their dissemination.
DRACMA’s influence on the subsequent literature
The original version, published in the World Allergy
Organization Journal (WAO Journal), was co-published in
Pediatric Allergy and Immunology (PAI) [6]. In 2011,
DRACMA was the most downloaded article from PAI web-
site, the second in 2012 and the third in 2013. The publica-
tion in the WAO Journal was the most accessed article in
2011 and 2012. The last available data (up to 2015) still in-
dicate that it ranks in the top ten. Up to August 15, 2017,
according the Scopus data, 241 articles cited the two ver-
sions. A summary report was published at the end of 2010
[7]. As for mid-august 2017, it has been cited 109 times
thus far, with a 6.57 Field-Weighted Citation Impact. The
systematic review proposing the recommendations for Oral
Immunotherapy in CMA [8] has been cited 103 times with
a 6.12 Field-Weighted Citation Impact. Thus, DRACMA
influenced heavily the subsequent literature on CMA.
DRACMA publications
After ARIA (Allergic Rhinitis and its Impact on Asthma),
DRACMA was the second guideline in allergy medicine
focused on important patient outcomes, explicitly taking
into consideration the patient’s values and preferences. It
pioneered in applying a systematic approach to collecting
the evidence, to separate the concepts of quality of evi-
dence and strength of recommendations, and to transpar-
ently report the decision process. The method used for
this CMA guideline was highlighted as an example of ap-
plication of the GRADE methodology in an article cited
58 times [9]. The application of such principles to the
diagnostic tests for CMA warranted a specific report,
which has been cited 42 times [10].
Other articles reported on the global burden of CMA
[11], and on its clinical aspects after the publication of
the guideline [12–14].
Guidelines on diagnosis and treatment of food allergy
before and after DRACMA
Prior to DRACMA, a handful of guideline documents for
food allergy diagnosis and treatment had been issued by the
main scientific societies in America and Europe [15–17].
National position papers and guidelines were available in
the Netherlands [18], Finland [19], Spain [20], France [21],
Germany [22] and Japan [23]. In general, these guidelines
were intended for specific countries and/or for specific geo-
graphical areas, so they took stock of local factors of epi-
demiological, economic, organizational, and social nature.
None of these documents used the GRADE methodology.
After 2010, other guidelines in the field of food allergy
were proposed. One of them made use of the GRADE
methodology in a way similar to DRACMA [24], another
used some form of GRADE [25], and others were
consensus-based documents [26–30]. Some national
guidelines were also updated or issued [31–34]. During
its 7 years, DRACMA was compared to other food
allergy guidelines, illustrating how the values and prefer-
ences expressed by the writing committees can modify the
recommendations [35, 36].
The number of citations may reflect the relevance of
the different food allergy guidelines: the most cited is
the National Institute of Allergy and Infectious Diseases
(NIAID) guideline [24] (392 citations, 5.17 Field-Weighted
Citation Impact). DRACMA stands second (241, 6.26),
followed by the European Academy of Allergy and Clinical
Immunology (EAACI) guidelines [25] (210, 18.68 Field-
Weighted Citation Impact).
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Guidelines on diagnosis and treatment of CMA before
and after DRACMA
By 2010, a few consensus documents provided guidance on
the diagnostic and therapeutic aspects of CMA in children
[37, 38]. National position papers and guidelines had been
produced in Germany [39, 40], Italy [41] and Argentina
[42], reflecting general and local needs and vision.
After the publication, 93 WAO-affiliated national Allergy
Societies endorsed the DRACMA guideline. Many of the
national meetings of these societies hosted lectures on
the topic. DRACMA was presented in many countries,
in US, France, Italy, Brazil, Chile, Argentina, Kenya,
Egypt, Thailand, and Indonesia, to name a few. In addition,
some Allergy Societies outside of WAO, e.g. the Iranian,
invited WAO lecturers to present on DRACMA. Following
the DRACMA explicit invitations to national implementa-
tion, some scientific and regulatory bodies did discuss and
actualize it in France [43, 44], United Kingdom [45, 46],
Middle East [47], South Africa [29, 30]. In Mexico, the
DRACMA recommendations were incorporated in a large
specific guideline [48].
In other cases, the DRACMA guidelines were directly
translated into the national languages, to overcome
language barriers. This happened in Italy [49], in South
America with the Spanish translation [50] and in China
[51]. The Mandarin translation was also discussed to be
actualized in the Chinese context [52].
After these discussions in many countries, DRACMA is
now the most cited CMA guideline, followed by the Euro-
pean Society for Paediatric Gastroenterology Hepatology
and Nutrition (ESPGHAN) guideline on cow’s-milk protein
allergy [53] (179 citations, 16.56 Field-Weighted Citation
Impact) and by the Italian CMA guideline [41] (51 cita-
tions, 4.02 Field-Weighted Citation Impact). The British
Society of Allergy and Clinical Immunology (BSACI) guide-
lines [46] score 4th (42 citations, 11.57 Field-Weighted
Citation Impact).
Economic consequences of DRACMA: Diagnosis
Among the diagnostic approaches proposed during the
phases of national adaptation, the British example is of
particular interest. In DRACMA, metanalyses of the
available literature allowed us to calculate the performance
characteristics of common diagnostic methods (skin prick
test [SPT] and specific IgE determination, at the cut-off
values of 3 mm wheal diameter and 0.35 kUA/L respect-
ively) vs. the Oral Food Challenge (OFC) reference test.
Assessing the clinical history, physicians can determine the
diagnostic likelihoods estimating the pre-test probability of
CMA. As examples, the pre-test probability will be low in
cases of atopic dermatitis or Gastroesophageal Reflux
Disease (GERD), average in case of immediate reactions
or high in case of anaphylaxis. The DRACMA guidelines
recommend – when possible – OFC for diagnosing CMA,
to avoid the risk of anaphylactic reactions at home in SPT
or sIgE false negative cases, unnecessary treatment for
false positive cases and inappropriate resource utilization.
However, some reasons (availability of appropriate staff,
organizational obstacles, resource availability, etc.) may
make it difficult to perform an OFC. In settings where
OFC is not considered possible or opportune, a pre-test
probability estimate may help physicians to reach a highly
probable diagnosis using simpler diagnostic tests such as
SPTs and/or specific IgE determination. These diagnostic
pathways however, allow a small chance of false positive
or negative results (Figs. 1 and 2) [13].
The cost of challenge test is reasonable in the majority
of cases. In the British context however, challenges were
considered "time-consuming and expensive" [46]. For
this reason, the BSACI guidelines indicated UK as a set-
ting where OFC is not considered an absolute require-
ment for the diagnosis of CMA. Taking stock of the
DRACMA assessment of the probability of false-
positive and false-negative diagnosis in case of high-
medium- and low- pretest probability, they recom-
mended the use of history (“typical” vs “non-typical”)
and SPT as rule-out and diagnostic tests in clinical
practice at the primary level. Especially for non IgE-
mediated CMA, they underline the role of dietary elimin-
ation for the diagnosis. This approach, limiting the role of
milk challenge to most doubtful cases, is similar to that pro-
posed by the ESPGHAN "practical" guideline, issued in
2012 [53]. This choice is perhaps cost-effective, but may ex-
pose patients to the risk of overdiagnosis. As an example, in
the Northern-Irish experience, the application of such strat-
egy resulted in a reduction of prescriptions for symptomatic
drugs for GERD, but in a steady increase in prescriptions
for special formulas [54]. Although one may surmise that
the diagnostic costs are reduced, the net costs for CMA
treatment increased in that community [55]. This example
illustrates how the application of a guideline can influence
real life practices and economics.
Fig. 1 In settings where OFC is not considered a requirement, should in
vitro specific IgE determination be used for the diagnosis of CMA in
patients suspected of CMA and a positive result of a skin prick test? [13]
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Economic consequences of DRACMA: Treatment
The DRACMA recommendations proposed an appropriate
substitute for different clinical situations. The question on
substitute formulas was the following: "Should amino acid
formula, extensively hydrolyzed whey or casein formula,
soy formula or rice formula be used in children with IgE-
mediated CMA?".
The answer to this clinical question was structured
through the recommendations in the box.
Box: DRACMA recommendations for CMA management
Recommendation 7.1
In children with IgE-mediated CMA at high risk of
anaphylactic reactions (prior history of anaphylaxis and
currently not using extensively hydrolyzed milk formula),
we suggest amino acid formula rather than extensively
hydrolyzed milk formula (conditional recommendation/
very low quality evidence).
Underlying values and preferences
This recommendation places a relatively high value on
avoiding possible anaphylactic reactions and a lower value
on avoiding the direct cost of amino acid formula in settings
where the cost of amino acid formulas is high.
Remarks
In controlled settings, a trial feeding with an extensively
hydrolyzed milk formula may be appropriate.
Recommendation 7.2
In children with IgE-mediated CMA at low risk of ana-
phylactic reactions, (no prior history of anaphylaxis or
currently on extensively hydrolyzed milk formula), we
suggest extensively hydrolyzed milk formula over amino
acid formula (conditional recommendation/very-low quality
evidence).
Underlying values and preferences
This recommendation places a relatively high value on
avoiding the direct cost of amino acid formula in settings
where the cost of amino acid formula is high. In settings
where the cost of amino acid formula is lower, the use of
amino acid formula may be equally reasonable.
Remarks
Extensively hydrolyzed milk formula should be tested in
clinical studies before being used. If a new formula is
introduced, one should carefully monitor if any adverse
reactions develop after first administration.
In structuring these recommendations, formulas were
rated according to a series of parameters. Among them,
the price was explicitly indicated as an important factor.
The DRACMA panel did a preliminary survey of the
mean cost of different types of formulas worldwide
(Table 1), from which it was found that feeding an infant
with an extensively hydrolyzed formula (eHF) was 2.5
times less expensive than using an amino acid-based
formula (AAF). Thus, even if the safety of AAF was
higher than eHF, the latter was indicated as the first
choice in CMA, except in cases of severe forms CMA
with high reactivity (anaphylaxis or eosinophilic esopha-
gitis), where AAF was recommended. Soy formulas (SF)
were considered less useful to avoid reactions to soy unless
they were more available and negative to skin testing.
Extensively hydrolyzed rice formula (eHRF) is probably
safer than eHFs, but it was considered at a lower level be-
cause it is not present in many countries (including UK).
As every recommendation reports the outcome that
was considered most relevant by the expert panel (Box 1),
they are flexible and can be subject to different interpreta-
tions when the importance of the outcomes in a particular
country, or for a particular patient, is different. As the cost
of the same formula differs substantially from country to
country [56], the implementation of the recommendations
may differ.
In recommendations 7.1 and 7.2, for example, cost makes
AAF a second choice when the clinical risk is lower (see
Fig. 2 In settings where OFC is not considered a requirement,
should in vitro specific IgE determination be used for the diagnosis
of CMA in patients suspected of CMA and a negative result of a skin
prick test? [13]
Table 1 Mean cost of special formulae worldwide, assessed in
October 2009 and used in DRACMA Guidelines, vs. price
structure in Italy after the DRACMA implementation [5]
Formula Cost
(€/liter)
Cost
(€ per month)
Cost
(€/liter)
Cost
(€ per month)
Cow’s milk 0.9 20 1.50 30
Cow’s milk formula 2.0 45 2.0 44
Soy formula 5 112 6 132
eHF 6.5 135 6.3 139
eHRF 6 135 7.5 165
AAF 14 318 12.8 281
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“values and preferences”). Elaborating on these consider-
ations, an Italian company decided in 2012 to decrease the
cost of their AAF by 30%, so that the cost of AAF dropped
from 2.4 to 2 times that of eHF. This did modify the balance
of recommendations for a substitute formula. AAF were
proposed to children with even less severe forms of
CMA, such as CM protein-induced atopic dermatitis.
This example illustrates how DRACMA guidelines
did influence the formula market, making appropriate
treatments affordable to larger layers of population.
Naturally, this is only one of the factors for an appro-
priate care. In some countries, patients are reimbursed
for AAF if “allergy” to eHF has been demonstrated, in
others there are no reimbursement policies. This can
expose to over-or under-use of special formulas.
Conclusions
DRACMA promoted a cultural debate among researchers
and clinicians, improving the quality of diagnosis and
clinical care. The accruing evidence on diagnosis and
treatment supports the need for an update. Ideally, the new
DRACMA guidelines should include non IgE-mediated
CMA, particularly mild-moderate forms of CMA and
chronic FPIES, as this part of the discipline has never been
subjected to the strictest criteria for EBM, using the
GRADE approach. We envisage the updated DRACMA
will answer more clinical questions, serving the patients’
and the pediatricians’ needs in the various contexts.
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